Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
TREST is a small-molecule oral tablet in pre-launch development by Novartis with NDA status. The mechanism of action, indications, and pharmacologic class are currently undisclosed. Patient population and therapeutic context remain to be determined at this stage.
Pre-launch stage signals active team building for launch infrastructure, including commercial planning, regulatory strategy, and promotional preparation roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
Worked on TREST at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TREST is in early pre-launch phase with no current job postings linked to the product. Career opportunities will emerge as Novartis moves toward regulatory approval and market launch, creating roles across medical, commercial, and regulatory functions.